新型24价肺炎球菌疫苗候选株在健康未接种肺炎球菌疫苗的日本成人中的安全性、反应原性与免疫原性:一项1期随机剂量递增试验
在日本开展的1期观察者盲法剂量递增试验中,54名20-49岁和72名65-85岁未接种肺炎球菌疫苗的成人分别接受单剂Pn-MAPS24v(1、2或5 μg/多糖,皮下或肌内)或PPSV23。未见安全性或反应原性担忧,无3-4级TEAE、严重AE或死亡;Pn-MAPS24v诱导的血清型特异性免疫应答与PPSV23相当或更高,皮下与肌内给药后相似。
要点
- 任何年龄组、剂量、给药途径或疫苗组均未发现安全性或反应原性担忧。
- 未报告3-4级TEAE、严重AE或死亡,所有疫苗相关TEAE均为轻度。
- 接种后1个月,Pn-MAPS24v诱导的血清型特异性免疫应答与PPSV23相当或更高。
核心结论
- Pn-MAPS24v显示出可接受的安全性特征,皮下和肌内给药后均具有免疫原性,支持其在日本进一步开发。
研究设计与样本
- 1期、剂量递增、观察者盲法试验,在日本开展。
- Stage 1纳入54名20-49岁未接种肺炎球菌疫苗的成人,按1:1(皮下:肌内)随机接受单剂Pn-MAPS24v,剂量为每多糖1 μg、2 μg或5 μg。
- Stage 2纳入72名65-85岁成人,按3:1(Pn-MAPS24v:PPSV23)和1:1(皮下:肌内)随机接受单剂Pn-MAPS24v(三个剂量之一)或PPSV23。
主要发现
- 任何年龄组、剂量水平、给药途径或研究疫苗组均未发现安全性或反应原性担忧。
- 未报告3-4级TEAE、严重AE或死亡;所有疫苗相关TEAE均为轻度。
- 疼痛、压痛和疲乏是最常报告的需求性AE。
- 接种后1个月,Pn-MAPS24v诱导的血清型特异性免疫应答与PPSV23相当或更高。
- 皮下和肌内给药后的免疫应答相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The burden of pneumococcal diseases remains high in Japan. Pn-MAPS24v is a novel MAPS-based vaccine containing complexes of 24 serotype-specific polysaccharides (PS), non-covalently coupled with fusion protein 1 (CP1). This study evaluated the safety and immunogenicity of different dose levels of Pn-MAPS24v, administered in Japanese adults either subcutaneously (SC) or intramuscularly (IM). METHODS: In this phase 1, dose-escalation, observer-blind trial conducted in Japan, 54 pneumococcal vaccine-naïve adults aged 20-49 years (stage 1), and 72 adults aged 65-85 years (stage 2) were sequentially enrolled. In stage 1, participants were randomized 1:1 (SC:IM) to receive a single Pn-MAPS24v dose at one of the dose levels (1 μg, 2 μg, or 5 μg per PS). In stage 2, participants were randomized 3:1 (Pn-MAPS24v:23-valent pneumococcal polysaccharide vaccine [PPSV23]) and 1:1 (SC:IM) to receive a single dose of either Pn-MAPS24v (one of three dose levels), or PPSV23. Solicited adverse events (AEs) were collected through 7 days post-vaccination, and treatment-emergent AEs (TEAEs) up to 1 month post-vaccination. Serotype-specific opsonophagocytic activity titers and immunoglobulin G (IgG) concentrations, as well as anti-CP1 IgG concentrations were measured before and 1 month post-vaccination. RESULTS: No safety or reactogenicity concerns were identified in any age category across groups. No grade 3-4 TEAEs, serious AEs, or deaths were reported. Regardless of the age category, dose level, administration route, or study vaccine, the frequency of reported TEAEs was low and all vaccine-related TEAEs were mild. Pain, tenderness, and fatigue were the most frequently reported solicited AEs. One month post-vaccination, Pn-MAPS24v induced serotype-specific immune responses that were comparable or higher than those elicited by PPSV23. The immune responses were similar after SC and IM administration. CONCLUSION: Pn-MAPS24v showed an acceptable safety profile and was immunogenic after SC and IM administration, therefore supporting the further development of Pn-MAPS24v in Japan. CLINICALTRIALS: gov: NCT04265911.
引用
- Borys D, Smulders R, Haranaka M, et al. Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial. Vaccine. 2024. PMID: 39612802. doi:10.1016/j.vaccine.2024.126545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。